Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.43 USD | -0.29% | -6.79% | +106.63% |
May. 30 | Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating | MT |
May. 07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
Evolution of the average Target Price on ADC Therapeutics SA
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering ADC Therapeutics SA
Cantor Fitzgerald | |
HC Wainwright | |
Guggenheim | |
RBC Capital Markets | |
TD Cowen | |
JPMorgan Chase | |
BofA Securities | |
Morgan Stanley | |
Wolfe Research |
EPS Revisions
- Stock Market
- Equities
- ADCT Stock
- Consensus ADC Therapeutics SA